logo

For the Inventor, By the Inventor

Molndal, Sweden

Staffan Po Karlsson

This inventor holds 15 USPTO granted patents and 6 published patent applications and 4 EPO patents, primarily in Cholesterol Inhibitors. Top assignee: Astrazeneca Ab. Active years: 2011-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Staffan Po Karlsson. Retrieved from https://idiyas.com/inventor/staffan-po-karlsson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15 

% Patents Active = 80.0

 

Average Co-Inventor Count = 9.8

ph-index = 5

Forward Citations = 72(Granted Patents)


Location History:

  • Molndal, SE (2011)
  • Mölndal, SE (2011 - 2024)

Company Filing History:

goldMedal15 out of 1,534 
 
Astrazeneca Ab
 patents

Years Active: 2011-2024

Loading Chart...
Loading Chart...
Areas of Expertise:
Dipeptidyl Peptidase 1
Cholesterol Absorption
2-Azetidinone Derivatives
Hyperlipidaemia
Pharmaceuticals
Oxazepane
Inhibitors
Drug Development
Bioactive Compounds
Medicinal Chemistry
15 patents (USPTO):Explore Patents
1. 12054465 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2024-08-06),
2. 11814359 - Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-11-14),
3. 11680049 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-20),
4. 11673872 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),
5. 11673871 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-13),
6. 11667615 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-06-06),
7. 11655224 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
8. 11655223 - Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
9. 11655221 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2023-05-23),
10. 11117874 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors (2021-09-14),
11. 10669245 - Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors (2020-06-02),
12. 7906502 - 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions (2011-03-15),
13. 7893048 - 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions (2011-02-22),
14. 7871998 - Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity (2011-01-18),
15. 7863265 - 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia (2011-01-04),

Title: **The Innovations of Staffan Po Karlsson: A Focused Inventor in Pharmaceutical Research**

Introduction

Staffan Po Karlsson, located in Mölndal, Sweden, is a distinguished inventor with an impressive portfolio comprising 15 patents. His work primarily focuses on pharmaceutical innovations aimed at addressing significant health challenges, particularly in respiratory medicine.

Latest Patents

Among his latest contributions to the field are two pivotal patents regarding certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides. These compounds have been identified as dipeptidyl peptidase 1 (DPP1) inhibitors. The significance of these inventions lies in their potential utility for treating and preventing clinical conditions, including respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Karlsson's work encompasses their therapeutic applications, the formulation of pharmaceutical compositions containing these compounds, and the processes involved in their preparation.

Career Highlights

Staffan Po Karlsson is currently affiliated with AstraZeneca AB, a leading global biopharmaceutical company known for its commitment to innovation in drugs and therapies. His ongoing research and development efforts are integral to AstraZeneca's mission to advance healthcare solutions.

Collaborations

Throughout his career, Karlsson has collaborated with esteemed colleagues including Stephen Connolly and Steven Swallow. These collaborations have facilitated the exchange of ideas and have enhanced the impact of his innovations in the pharmaceutical industry.

Conclusion

Staffan Po Karlsson exemplifies the role of an innovative inventor in the realm of pharmaceutical development. His contributions, particularly in the formulation of DPP1 inhibitors, underscore the importance of research and patenting in addressing complex health issues. With a strong foundation in collaboration and a commitment to improving patient care, Karlsson continues to be a valuable asset to the scientific community and the broader field of medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…